AR Asset Management Inc. Takes $729,000 Position in Novo Nordisk A/S (NYSE:NVO)

AR Asset Management Inc. bought a new stake in Novo Nordisk A/S (NYSE:NVO) during the first quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 10,500 shares of the company’s stock, valued at approximately $729,000.

A number of other large investors also recently modified their holdings of the stock. Strategic Investment Solutions Inc. IL increased its position in shares of Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company’s stock valued at $27,000 after acquiring an additional 300 shares during the last quarter. Copeland Capital Management LLC increased its position in shares of Novo Nordisk A/S by 184.8% during the first quarter. Copeland Capital Management LLC now owns 393 shares of the company’s stock valued at $27,000 after acquiring an additional 255 shares during the last quarter. North Capital Inc. purchased a new stake in shares of Novo Nordisk A/S during the first quarter valued at approximately $27,000. Park Square Financial Group LLC purchased a new stake in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $29,000. Finally, Stone House Investment Management LLC purchased a new stake in shares of Novo Nordisk A/S during the first quarter valued at approximately $30,000. Institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

A number of analysts recently commented on NVO shares. Dbs Bank downgraded Novo Nordisk A/S to a “sell” rating in a research report on Friday, April 25th. BNP Paribas raised Novo Nordisk A/S from an “underperform” rating to a “neutral” rating in a research report on Wednesday. Hsbc Global Res downgraded Novo Nordisk A/S from a “strong-buy” rating to a “hold” rating in a research report on Thursday, July 31st. Wall Street Zen cut Novo Nordisk A/S from a “buy” rating to a “hold” rating in a research report on Saturday, August 2nd. Finally, BNP Paribas Exane upgraded Novo Nordisk A/S from an “underperform” rating to a “neutral” rating and set a $54.00 price target for the company in a research report on Wednesday. One research analyst has rated the stock with a sell rating, twelve have assigned a hold rating and two have issued a buy rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Hold” and a consensus target price of $83.75.

Novo Nordisk A/S Trading Up 2.9%

Shares of NVO stock opened at $52.43 on Friday. The company has a quick ratio of 0.56, a current ratio of 0.78 and a debt-to-equity ratio of 0.52. The business has a 50-day moving average price of $64.96 and a two-hundred day moving average price of $70.44. Novo Nordisk A/S has a 12-month low of $45.05 and a 12-month high of $139.74. The firm has a market cap of $234.10 billion, a P/E ratio of 14.40, a price-to-earnings-growth ratio of 1.75 and a beta of 0.63.

Novo Nordisk A/S (NYSE:NVO) last released its quarterly earnings data on Wednesday, August 6th. The company reported $0.97 EPS for the quarter, topping the consensus estimate of $0.93 by $0.04. The firm had revenue of $11.69 billion for the quarter, compared to the consensus estimate of $77.51 billion. Novo Nordisk A/S had a return on equity of 78.64% and a net margin of 35.60%. Equities analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The business also recently disclosed a semi-annual dividend, which will be paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th will be issued a $0.4119 dividend. The ex-dividend date is Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S’s payout ratio is currently 45.05%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.